Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. - Wikidata - wikimedia - TriplyDB

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

http://www.wikidata.org/entity/Q34289502

about

Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis Ozagrel hydrochloride, a selective thromboxane A₂ synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice.Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names Revisiting the usefulness of thromboxane-A2 modulation in the treatment of bronchoconstriction in asthma.Targeting the PGD2/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives.Assembling NMR structures for the intracellular loops of the human thromboxane A2 receptor: implication of the G protein-coupling pocket.JTE-852, a novel spleen tyrosine kinase inhibitor, blocks antigen-induced allergic reactions in rats.

P2860

Q24630614-E101D51A-A14F-4830-B85E-565C707E07CD Q34567487-06845E45-1793-4468-A5E7-B19ABFAA08BA Q35663953-FC3F6DA1-2EF9-44C5-9B3F-B3CD08C2FF69 Q35877936-931B3C3A-3523-4A26-85C5-64F6A466EB5D Q38315250-DE2358F7-5BBF-4B95-AE43-AA3890365286 Q38671252-C7959955-5DE5-4B01-BB17-07DD3C4632BF Q42151146-1A484D91-BD06-4EDD-B237-7F89953439DC Q49635004-C72A5884-8EE8-4745-B488-542C7438248C

P2860

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

http://www.wikidata.org/entity/Q34289502

description

2002 nî lūn-bûn

@nan

2002 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@ast

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@en

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@nl

type

label

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@ast

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@en

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@nl

prefLabel

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@ast

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@en

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@nl

P1433

Q34289502-F0EFFE0E-9AC6-4556-8DAA-5BF1E3720B31

P1476

Q34289502-82D8D3B8-3F95-4FA0-9D79-502E3E57588D

P2093

Q34289502-4238C2CD-8E47-411F-8BA0-86DB568B6596

Q34289502-5360A722-B08A-436E-952D-B419F6CEC318

Q34289502-5951CC2E-2A9A-4256-B0BA-02EA860D130B

Q34289502-E3502C13-FD11-4794-BC93-06E453231010

Q34289502-EC41A1FA-543F-4D51-BA31-34492C8D3561

P2860

Q34289502-06704CE4-C2C5-40E0-9ADF-AF809037A47C

Q34289502-1AC7B8D3-B274-4A2E-A4A4-6E9263A95E26

Q34289502-270F112F-F4AB-4DDB-A54A-60428583FB52

Q34289502-2C7420AF-8F19-49B9-B5CF-AF259F2ED743

Q34289502-2F713430-10EC-40BA-BE35-9F6AC1A62DEC

Q34289502-3F75834B-37A8-4B7E-8547-5CC9C4DF9CFB

Q34289502-429AFE4C-20C6-42A3-9081-E63F3981E24B

Q34289502-4FE6728A-2487-4A17-8791-ECF6CA64D034

Q34289502-5CC1105F-BA11-43BB-B8E3-A77DB1E88712

Q34289502-64CDA34F-23AB-4F57-B66D-25C56A23161B

P2888

Q34289502-265C45BF-28E8-42DF-A6E0-F3A704C1F792

P304

Q34289502-3FEA1108-79EB-4290-9A66-9AAC529982D4

P31

Q34289502-1D70A486-3538-40B5-BA9D-A00C08CE974D

Q34289502-f3a8d93a-0774-41ac-97e0-559f7a4c8bcc

P356

Q34289502-608E02F4-7788-4706-9321-B2868CE6D33C

P433

Q34289502-3B22504D-4BCD-47EE-900B-CA781CF582E7

P478

Q34289502-75DDEA57-56AC-4568-88BE-B8B9C2E714CD

P577

Q34289502-FC3D82A6-417A-4F2F-8F84-9FB5CDBB6A51

P698

Q34289502-21FE4021-3500-46B2-BD27-B9C78A9F9E5A

P921

Q34289502-00E4711D-D623-433B-A862-C614DAC9424F

P356

P1433

Treatments in Respiratory Medicine

P1476

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

@en

P2093

Bernard Masereel

http://www.w3.org/2001/XMLSchema#string

Jacques Delarge

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Dogné

http://www.w3.org/2001/XMLSchema#string

Patricia Benoit

http://www.w3.org/2001/XMLSchema#string

Xavier de Leval

http://www.w3.org/2001/XMLSchema#string

P2860

Thromboxane A2 and related prostaglandins in airways

Arachidonic acid metabolism by human monocytes. Studies with platelet-depleted cultures

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

Biochemistry and physiology of the leukotrienes.

Role of leukotrienes in asthma pathophysiology.

Leukotriene receptor antagonists in the treatment of asthma.

Discovery of leukotrienes and development of antileukotriene agents.

Efficacy of antileukotriene agents in asthma management.

The effects of an oral thromboxane TP receptor antagonist BAY u 3405, on prostaglandin D2- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations

Quinones. 4. Novel eicosanoid antagonists: synthesis and pharmacological evaluation.

P2888

P304

11-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF03257158

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2002-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14720071

http://www.w3.org/2001/XMLSchema#string

P921